臨床泌尿器科60巻12号

2006年11月発行

特集 ここが知りたい―癌薬物療法

進行性精巣腫瘍に対する化学療法

著者： 野々村祝夫¹ 奥山明彦¹

所属機関： ¹大阪大学大学院医学系研究科器官制御外科学（泌尿器科）

ページ範囲：P.907 - P.913

文献概要

　進行性精巣腫瘍の治療に関して，CDDPの開発が大きな転帰となったが，EinhornらによるPVB療法の報告以後，進行性精巣腫瘍の治療成績は飛躍的に向上した。その後，WilliamsらによるBEP療法の報告で，導入化学療法の基盤ができた。1997年に発表された国際的risk分類であるIGCCC（International Germ Cell Consensus Classification）分類の導入以後，risk別に治療成績が検討されるようになった。Good risk群に対しては，少しでも副作用を軽減するような臨床試験が行われ，Poor risk群に対しては，大量化学療法や，様々な新規抗癌剤を組み合わせた新しい治療レジメンによる治療が試みられつつあり今後の報告が期待される。

参考文献

1）Einhorn LH and Donohue JP：Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87：293-298, 1977

2）Vugrin D, Herr HW, Whitmore WF Jr, et al：VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Intern Med 95：59-61, 1981

3）Williams SD, Birch R, Einhorn LH, et al：Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316：1435-1440, 1987

4）International germ cell cancer collaborative group：International germ cell consensus classification：a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15：594-603, 1997

5）Einhorn LH, Williams SD, Loehrer P, et al：Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors：A Southeastern Cancer Study Group Protocol. J Clin Oncol 17：387-391, 1989

6）Bosl GJ, Geller NL, Bajorin D, et al：A randomized trial of etoposide＋cisplatin versus vinblastine＋bleomycin＋cisplatin＋cyclophosphamide＋dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 16：1231-1238, 1988

7）Xiao H, Mazumdar M, Bajorin D, et al：Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15：2553-2558, 1997

8）Loehrer PJ Sr, Johnson D, Elson P, et al：Importance of bleomycin in favorable-prognosis disseminated germ cell tumors：An Eastern Cooperative Oncology Group Trial. J Clin Oncol 13：470-476, 1995

9）Nichols CR, Williams SD, Loehrer PJ, et al：Randomized study of cisplatin dose intensity in poor-risk germ cell tumors：A Southeastern Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 9：1163-1172, 1991

10）Kaye SB, Mead GM, Fossa S, et al：Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumors：A randomized Medical Research Council/European Organization for Rsearch and Treatment of Cancer Study. J Clin Oncol 16：692-701, 1998

11）Nichols CR, Catalano PJ, Crawford ED, et al：Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors：An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16：1287-1293, 1998

12）Hinton S, Catalano PJ, Einhorn LH, et al：Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors：final analysis of an intergroup trial. Cancer 97：1869-1875, 2003

13）Motzer RJ, Mazumdar M, Bajorin DF, et al：High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15：2546-2552, 1997

14）Motzer RJ, Mazumdar M, Gulati SC, et al：Phase Ⅱ trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85：1828-1835, 1993

15）Bokemeyer C, Kollmannsberger C, Meisner C, et al：First-line high-dose chemotherapy comapred with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors：A multivariate and matched-pair analysis. J Clin Oncol 17：3450-3456, 1999

16）Nichols CR, Andersen J, Lozarus HM, et al：High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer：An Eastern Cooperative Oncology Group Protocol. J Clin Oncol 10：558-563, 1992

17）Siegert W, Beyer J, Stroscheer I, et al：High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer：A phaseⅠ/Ⅱ Study. J Clin Oncol 12：1223-1231, 1994

18）Motzer RJ, Mazumdar M, Bosl GJ, et al：High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors：Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14：1098-1105, 1996

19）Beyer J, Kingreen D, Krause M, et al：Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79：161-168, 1997

20）Kollmannsberger C, Rick O, Klaproth H, et al：Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer：a phaseⅡ study of the German Testicular Cancer Study Group. Br J Cancer 87：729-732, 2002

21）Miki T, Mizutani Y, Nonomura N, et al：Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 95：1879-1885, 2002

22）Pectasides D, Pectasides M, Farmakis D, et al：Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients：a phase Ⅱ study. Eur Urol 46：216-221, 2004

23）Motzer RJ, Bajorin DF, Schwartz LH, et al：Phase Ⅱ trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. Clin Oncol 12：2277-2283, 1994

24）Bokemeyer C, Beyer J, Metzner B, et al：Phase Ⅱ study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7：31-34, 1996

25）Motzer RJ, Sheinfeld J, Mazumdar M, et al：Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18：2413-2418, 2000

26）Rick O, Bokemeyer C, Beyer J, et al：Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19：81-88, 2001

27）Einhorn LH, Stender MJ and Williams SD：Phase Ⅱ trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17：509-511, 1999

28）Pizzocaro G, Nicolai N, Salvioni R, et al：Paclitaxel, cisplatin, gemcitabine third line therapy in metastatic germ cell tumors of the testis. Ann Oncol 12（suppl 4）：38, 2002

29）Kollmannsberger C, Beyer J, Liersch R, et al：Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer：a study of the German Testicular Cancer Study Group. J Clin Oncol 22：108-114, 2004

30）Hinton S, Catalano P, Einhorn LH, et al：Phase Ⅱ study of paclitaxel plus gemcitabine in refractory germ cell tumors（E9897）：a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20：1859-1863, 2002

31）McCaffrey JA, Mazumdar M, Bajorin DF, et al：Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors：Response and survival. J Clin Oncol 15：2559-2563, 1997

32）Loehrer PJ Sr, Gonin R, Nichols CR, et al：Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16：2500-2504, 1998

33）Broun ER, Nichols CR, Gize G, et al：Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79：1605-1610, 1997

34）Bhatia S, Abonour R, Porcu P, et al：High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18：3346-3351, 2000

35）Miki T, Mizutani Y, Akaza H, et al：Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.（Submitted）